Chapter 4: Jonathan - Forced Marriage to the CEO

Jonathan

“That’s wrong,” Elizabeth says, not looking up from her own copy of the briefing. “Try it again.” We’re four hours into mock panel questions and I’ve missed the same category of question twice now. My answers are reflexive and defensive. Right now the imprecise phrasing I’m using could be pulled apart by a panelist in front of six cameras and a room full of investors. Elizabeth Kline, our Chief Scientific Officer does not tolerate imprecision on a good day. This is not a good day.

“The secondary endpoint data supports the primary finding,” I say again, slower.

“It doesn’t support it. It’s consistent with it. Those are not the same claim, and if you say ‘supports’ to Richards on the panel she will ask you to define your terms in front of everyone, and you will not have a good answer, because there isn’t one. You know this. You wrote the protocol.” She sets her pen down with more force than the pen requires. “Where are you today?”

“I’m right here.”

“You are not.” She’s not raising her voice. Elizabeth never raises her voice; she simply becomes more exact, which is somehow worse. “I’ve watched you handle panels with a fever. I’ve watched you do this after four hours of sleep. You do not miss endpoint distinctions. Something is sitting in your head that isn’t this briefing, and we now have less than twelve weeks and I would like to know what it is before it costs us a question we can’t recover from in front of the FDA.”

I don’t answer right away. She reads the silence accurately, but not completely.

“You have to meet with Harlan today, don’t you.” It isn’t a question. As heir apparent to this company, she’s read the same trust language I have, sat through the same warnings about the clause from the beginning countdown. “That’s what this is. The board finally putting the calendar in front of you.”

“That’s part of it.”

“Jonathan.” She looks at me directly now, and there’s nothing soft in it, which is exactly why I trust her more than anyone else in this building. “I don’t care what happens to your personal life. I care that whatever it is doesn’t happen in front of an advisory committee. If you need to marry someone to make a governance clause go away, marry someone. Just don’t bring it into this room again until it’s handled. The data has to be the only thing in your head by the time you’re in that hearing, or nine years of work gets read as instability because you couldn’t separate the two.”

She’s not wrong but she’s just not entirely right either, and I don’t correct her. Regardless, I am not nailing down the perfect verbiage to secure an AdComm approval and that is the bottom line.

“Understood.”

“Good. Page eleven. Try the endpoint answer again, and this time say what’s actually true instead of what sounds better.”

I try it again. It’s better, but isn’t good enough, and we both know it. But we keep going anyway because that’s the only response we’ve ever had to a problem is to keep working until it’s precise, whatever it costs to get there.

My assistant buzzes through near the end of the session. Harlan’s called ahead to schedule the conference room for four o’clock with Richard Chao, independent board chair, and Patricia Webb, outside counsel as well.

“Go deal with Harlan.” She’s already back to the briefing. “Then go home, or wherever it is you go when something’s wrong. Come back tomorrow with your head straight and we’ll run it again.”

I don’t tell her I don’t know where that is anymore.

* * *

I call Harlan from the lobby and push the meeting to a call tonight. I want to keep it informal, just the two of us. He doesn’t ask why. Harlan has been reading Atwell men long enough to know when one of us needs room to think before he needs to be held accountable.

The drive to Weston takes forty minutes on a good day, longer with the kind of traffic that gives a man too much time alone with his own thoughts. I take the back roads instead, the ones that wind past the reservoir, because I’d rather have the extra ten minutes than the extra thinking.

My grandfather is on the porch when I pull in, a blanket over his knees despite the mild afternoon, a crossword folded open on his lap that he hasn’t touched. He looks up before I’m fully out of the car, and something in his face eases the moment he recognizes me. We walk to the back that overlooks the lake. He likes to sit there when the weather permits. He sits in his favorite chair with his blanket and crossword, and I sit next to him. I pull my chair closer and we talk about ordinary things: the labs, the unusually warm fall, and the Red Sox. Neither of us follows baseball closely enough anymore to justify strong opinions, but the mundane rhythm is a relief.

His eyes drift toward the lake. “You still working too much?”

“According to everyone who works for me.”

He chuckles. “Good.”

I smile. “You’ve never once told me to work less.”

“No.” He folds his hands across his lap. “I told you to work on something worth doing.”

I look over at him and remember the conversation. I left the commercial division nine years ago, and almost everyone thought I’d made the worst decision of my career. The analysts called it reckless, the board called it unnecessarily expensive, and investors wanted oncology, cardiology or anything else with predictable returns.

Instead, I poured more than four hundred million dollars into one of the hardest problems in medicine. No one in my family had ever received that kind of diagnosis. I simply could not ignore the reality that so many other families already had. I’d spent enough years turning successful companies into more successful ones. Money had never been the difficult part. What kept me awake was the possibility of giving someone another year with the person they loved. That, finally, felt like the only problem worth solving.

“You still chasing impossible things?” my grandfather asks.

“Every day.”

He nods once. “Good. Somebody should.”

I can’t answer.

The silence between us is comfortable; it always has been. He reaches for the crossword and studies one clue, then frowns.

“So…” Another pause. “Have you spoken to your father? About the succession?”

We are not having this conversation. We settled this nine years ago and he was there.

I say nothing. He keeps looking at the glassy water, searching for something only he can see.

The seconds stretch from one to two and longer, then his shoulders shift almost imperceptibly as he turns back toward me, and recognition returns along with shame.

“I’m sorry.” His voice is so quiet and small.

“I know.”

He looks down at his hands. “I hate when that happens.”

There are no words of comfort I can offer. “I know.”

Neither of us says the word, we don’t need to. We sit together a while longer. He doesn’t try to pretend it didn’t happen, and I don’t try to rescue him from it. Eventually, I stand. He catches my wrist before I can leave. His grip isn’t what it used to be, but it’s still his.

“You’ll finish it, the work.” His eyes are clear again. “They’re lucky you didn’t choose the easy road.”

My throat tightens. “I don’t know if we’re going to get there in time.”

He smiles. “You’ve never quit because something was hard, don’t start now.”

“No, I won’t.”

As I leave, Mrs. Calloway, his caregiver, comes to the car. “He’s having more mornings like that and they’re lasting longer.”

“I noticed.”

Nearly a decade ago, my grandfather insisted I could build whatever future I wanted. He protected that future the only way he knew how: with lawyers, trusts, and a clause he believed would keep the company in responsible hands. Now, he can barely remember the conversations that created it. Ironically, the clause he wrote to protect my future now threatens the company fighting the disease stealing his past.

I get into the car and realize I have less than twelve weeks more to prepare for AdComm. Millions of families are waiting for an answer, one of them just became mine.

* * *

Harlan calls at six, brief, almost apologetic.

“I don’t need an answer tonight,” he says. “I just need to know you’re taking this seriously.”

“I’m taking it seriously, Harlan.”

“I know you are.” A pause, the sound of him deciding whether to say more. “Your grandfather built that clause because he believed in you more than he trusted anyone else to protect what you’d build. I don’t think he ever imagined it would be the thing standing in your way.”

“I’ll have an answer soon,” I say, and it isn’t a deflection. I already know what the answer is. I’m just not ready to say her name out loud to anyone yet.

* * *

The short position has been on my radar for seventy-two hours. It’s when someone bets that your stock price will go down so they make a profit when it does. It’s not long enough to be certain, but it’s long enough to worry me. One or more people is actively betting that our gene therapy NovaClear will fail. If we don’t get a positive vote at AdComm, the stock price will drop, and they’ll make a great deal of money from our loss.

I’d asked David, my head of finance, to find out who. He’s waiting in my office when I get back, a laptop open, and a look on his face I don’t like.

“Show me where we are,” I say, without preamble.

“It’s not one position,” David says, pointing to the laptop screen. “It’s three, spread across two prime brokers and a family office. Structured so no single filing crosses the disclosure threshold on its own. On the surface they look completely unrelated. They are different entities, have different vehicles, and different timing.” He pauses. “But the architecture is the same. Whoever built this used the same thinking each time. Same logic, same margin of visibility they were willing to accept. That’s not coincidence, that’s one hand.”

I study his screen which displays trading records and dates that show a pattern assembled slowly over the six weeks that you would not have seen unless you actively watched for it to catch. Which is exactly what David’s been doing since the first flag came through.

“But you can’t trace it to a name yet.”

“Not yet.” He says. “But Boston’s small enough that money like this doesn’t move without somebody noticing eventually. A guy at Ashfield Securities mentioned something offhand to me a couple of weeks ago, but I didn’t think it mattered at the time. I’ll call him back and pull that thread.” He closes the laptop. “I need more time.”

I don’t say anything for a moment as I think about one hand. We’re dealing with someone who understood how the disclosure thresholds worked, exactly how much time they had, and precisely what the AdComm window meant for the stock. That wasn’t a random bet against a biotech. That was someone who knew where to push.

“Keep pulling,” I say. “Quietly. I don’t want this going anywhere until you have something airtight.”

“Understood.” He stands, then leaves my office.

After he leaves, I sit alone with the numbers for a long time, turning over a single, unpleasant certainty: whoever is on the other end of this position understood the AdComm timeline well enough to build against it before most of my own board had marked the date. That’s not a stranger, that’s someone close.